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Abstract 
We used a retrospective modeling approach instead of the traditional farm to fork model; back 
calculating (Cm) the number of human macrolide resistant C. coli mfections caused by eating 
contaminated pork, due to specific macrolide use in swine. We used the estimated number of 
culture confirmed human infections (Ct). As a measure of human health risk, we then calculated 
the expected number among the (Cm) cases that experience an adverse treatment outcome 
(prolonged illness) due to macrolide resistance, using estimates for fluoroqu inolone. We divided 
the model into Release, Exposure and Consequence assessment sections according to FDA 
guidance 152 and utilized @Risk software with 20,000 iterations for simulation. The results show 
the human health risks are negligible. For example, the predicted annual risk, for preventton and 
growth promotion uses is only 1 in 92 million per U.S. resident, with a 5% chance it could be as 
high as 1 in 52 million. Our model focuses on the impact of resistance on human treatment. It 
assumes that macrolide resistance C. coli infection reduces treatment efficacy. However, it is 
possible that risks less than our estimates. 
Introduction 
Campylobacter is considered an important food-borne pathogen. Erythromycin. a macrolide 
antibiottc, is recommended for the treatment and control of severe culture confirmed 
campylobacteriosis. Recent studies have reported higher frequencies of resistant Campylobacter 
in conventional swine farms compared to antibiotic free farms. There are concerns that macrolide 
antibiotic use on swine farms may increase human health risk. Our objective was to conduct a 
stochastic quantitative risk assessment of potential adverse health outcomes due to macrolide 
resistant C. coli infection originating from macrolide use on the swine farm. 
Materials and Methods 
We chose a retrospective modeling approach instead of the traditional farm to fork model which is 
significantly more data intensive. Hence, we back calculated (Cm) the number of human macrolide 
resistant C. coli infections caused by eating contaminated pork, due to a specific type of macrolide 
use in swine. We started with estimated number of total culture confirmed human tnfections (Ct). 
As a measure of human health risk, we then calculated the expected number among the Cm cases 
that might experience an adverse treatment outcome due to macrolide resistance. An adverse 
treatment outcome refers to ineffective treatment resulting in prolonged illness such as extra days 
of diarrhea or fever. We divided our model into Release, Exposure and Consequence assessment 
secttons according to FDA guidance 152 (www. fda.qov/cvm/guidance/fquide152 DOC). We 
utilized a variety of uncertainty distributions for the parameters and simulated with @Risk software 
(20,000 iterations). 
Release Assessment: In th is section , we calculated the fraction of C. coli population 1n swine that 
is macrolide resistant due to different types of macrolide (rm). Following we describe the estimatton 
of rm for prevention and growth promotion uses (Tylan Premix® and Tylan Sulfa-G ®) followed by 
the estimation for treatment and control uses (Tylan Injection®, Tylan Soluble® and Pulmotil 
Premix®) 
Let rb be the background resistant fraction that exists without exposure to macrol ide, and r1 be the 
steady state resistant fraction in a conventional farm in which a fraction (a) of the swine have been 
exposed to a specific macrolide. The total resistant fraction (r1) is linearly related to the fract1on 
exposed (a) as a first order approximation shown m Equation 1. 
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(1) 
Where , the constant (p) corresponds to the probability that a bacterium among the fraction a(1-rb) 
of the C. coli population that is susceptible, acquires res1stance or 1s replaced by a resistant 
bactenum. The term a(1-rb)P IS equal to (rm). the fraction resistant due to macrolide use 
To est1mate p, we used the difference 1n the resistant fractions between antib1otic free (ABF) farms 
and conventional farms (using macrol1de). Two studies reported 38% of 745 C coli isolates from 
ABF farms and 77% of 347 C. coli Isolates from conventional farms (r1) were resistant (Gebreyes 
et al , 2005 and Thakur and Gebreyes 2005). Hence, we estimated rb = 38% and r, = 77% (Mean of 
the Beta distributions in Table 2). We assumed that all the animals in the conventional farms were 
exposed to macrolide i.e. a =1 . By solving Equation 1, we calculated p = 62% for prevention and 
growth promotion uses. From industrial usage data, the overall national fraction of swine exposed 
for prevention and growth promotion uses was 58% (Doane, 2005). Finally, we computed, rm=21% 
(resistance in C. coli 1n sw1ne that 1s due to macrolide use). 
For estimation of p due to treatment uses, we had to use data on Enterococci spp. Jackson et al , 
2004 found that the resistant fraction in Enterococci spp. from farms that used macrolide for 
prevent1on alone was tw1ce of that 1n farms with treatment uses. Therefore, we assumed (p) for 
treatment uses is 31% or half of the (p) for prevention or growth promotion uses. 
Exposure assessment: For the Exposure assessment, we estimated the number of culture-
confirmed human C. coli infections that are resistant due to macrolide use 1n swme (Cm) utilizing 
Equation 2. 
C .. = C,l] r (2) 
Where, the population etiologic fraction (17) is defined as the fraction of human mfect1ons caused by 
C. coli from swme. Total number of culture confirmed human C. coli infections per year is C1• 
To calculate the etiolog1c fraction (17) for sw1ne, we conservatively (Risk increasing) assumed that 
all the C. coli infections (C1) are caused by eating only chicken or pork, then distributed the cases 
according to relat1ve carcass contamination rates. Table 1 provides the data sources, and the 
estimated values of the parameters utilized in calculating f] . To estimate the kilograms of 
contam1nated pork, we assumed that all ground pork from a contaminated sw1ne carcass is 
contaminated , while the non ground pork is not. For kilograms of contaminated chicken we 
assumed all serv1ngs from a contaminated carcass were contaminated As a result, we calculated 
that 12.4% of the human C. coli Infections are caused from swine. 
Table 1 Estimation of etiolo ic fraction for C. coli for swine and chicken 
Parameter Details 
Carcass contamination rate of Campylobacter spp 
Food safet and Ins ection serv1ce 1994 
Fraction of C.coli among Campylobacter spp isolates 
(NARMS· Nallonal Antimicrobial Res1stance 
Monitorin S stem retail 2002-2003 
Fraction of carcasses contaminated with C. coli 
Expected Fraction of sw1ne carcass processed into 
round meat Hurd et al. , 2004 
Overall fraction C coli contaminated meat servmgs 
after slau hter 
Annual kilograms of meat produced (~ational 
A ricultural Stat1St1cs Serv1ce, 2006 
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30% 
Beta(231 ,527) 
27% 
100% 
27% 
16 billion 
32% 
21% 
6.72% 
9.3 btllion 
Safepork 2007- Verona (Italy) 15 
Consequence assessment: We calculated the annual number of adverse outcomes due to 
macrolide use (Cao) according to Equation 3. Where r is the joint probability that a culture 
confirmed infection is treated with an antibiotic and the prescribed antibiotic is macrolide The 
parameter, p, IS the probability that adverse outcome occurs due to macrolide resistance. 
(3) 
We are unaware of any evidence that macrolide resistant Campylobacter causes any more illness 
days than susceptible or that erythromycin treatment has any clinical benefit, i e. p is likely zero. 
However, to be conservative, we utilized fluoroquinolone data to estimate p; erroneously assuming 
that macrolide and fluoroquinolone resistant 1nfect1ons have identical clinical consequences. 
Table 2 Parameter estimates and risk assessment of adverse treatment outcomes to C.co/i 
infections that are resistant due to macrolide use in swine 
Prevention and 
Parameter Growth promotion Treatment All uses 
... ( :,J[:.J-:1-"1,..!.\' 
a, Fraction of an1mals 58% 17.3% 
exposed to macrolide 
rb. Background 38% 
resistance Beta(229,518t 
r1, Res1stant fraction in r1=77% 
farms utiliztng macrolide Beta{12,823)* 
P, Probability of 62% 31 2% 
res1stance development 
rm. Fraclton res1stant 21% 33% due to macrolide use 
Ex osure Assessment 
Annual number of 
Campylobacter spp 
cases (culture-
confirmed) 
38,315 Gamma(5665,1)6.76* 
Fraction of human 
Campylobacter cases 
caused by C coli 
C1, Annual number of C 
colt cases 
fl , Et1olog1c fraclton 
Cm. number of cases 
rests/ant due to 
macro/de I 
Consequence 
Assessment . 
4 3% Beta (64,1409)" 
1647 
12.40% 
46 7 
r Probability that a 
culture confirmed case IS 
treated w1th a macrolide 
p Probab1l1ty of an 
adverse outcome g1ven 
macrolide res1stance 
32% 
Beta{320,501 }Beta(938, 193t 
C.o Annual number of 
22% 
Beta{7,24)* 
adverse outcomes 3 23 (1 61 -5 65) 0 5(0 23-
medlan 0 84 
Annual nsk of an 1 1n 
adverse outcome for a 1 1n 92 (52-184) 620{354-
person in the US m1llion 1250) 
median million 
53 0 
11n 80 
{45-162) 
million 
Data sources 
Doane marketing 
survey (2005) 
Gebreyes et al , 
(2005);Thakur and 
Gebreyes {2005) 
Foodnet2004 
Gupta et al , 2004 
Nelson et al., 2004 
Kushner et al • 
1995; Sanders et 
al , 2002 
Confidence Intervals provided are two sided at 90% confidence The human health consequences are g1ven 
as med1ans Annual nsk was calculated as the ratio of the US populat1on of 298 millton/Cao • These are 
uncerta1nty d1stnbulions for the parameter estimates wh1ch were Simulated us1ng @R1sk® software 
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G=l 
Results fS 
The parameter estimates, their distributions, data sources, the results for the risk assessment are @ 
summarized in Table 2. The median risk of an adverse treatment outcome due to macrolide use oJ= 
induced resistance in C. coli from swine is less than 1 in 80 million. The risk is less than 1 in 45 
million with 95%. The risk due to treatment uses is negligible and is less than 1 in 354 million with 
95% confidence. 
Discussion 
Our results show that at worst, the human health risk due to macrolide induced resistance in C. coli 
from swine is very low even with the conservative assumptions we made. Reasons for the low risk 
include the low fraction of human infections caused by C. coli and the relatively higher C. coli 
contamination rate of chicken carcass. Furthermore, the risk due to treatment uses is negligible as 
only a very small fraction of swine is exposed to it. We had to make very conservative assumptions 
such as that all the C. coli infections are caused from chicken or swine due to the lack of data on 
the etiologic fraction. More data on the etiologic fraction and the clinical consequences of 
erythromycin resistance is required. In addition, Sensitivity analysis showed that the fraction of 
human infections caused by C. coli and macrolide resistant fractions in conventional and ABF 
farms are other parameters leading to a significant uncertainty in the resulting risk estimates, 
demonstrating the need for further research in this area. 
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